RNA干扰ABCE1基因后可增加肺癌95-D/NCI-H446细胞的E-钙黏附蛋白表达并减低细胞侵袭力

研究ABCE1对肺癌(95-D和 NCI-H446)细胞的作用．使用RNA干扰技术,抑制ABCE1基因的表达,通过Western blot 分析及FACS检测,观察ABCE1基因对E-钙黏附蛋白在95-D/NCI-H446细胞表达的影响;运用transwell 侵袭实验,观察M95-D/ NCI-H446细胞侵袭力的变化．RNA干扰ABCE1基因后,实验组与对照组相比,在48 h后可显著抑制肺癌(95-D和 NCI-H446)细胞ABCE1蛋白的表达,同时,伴随E-钙黏附蛋白的高表达,以及细胞侵袭力的降低． ABCE1基因与E-钙黏附蛋白相关,抑制ABCE1基因可增加肺癌95-D/NCI-H446细胞的E-钙黏附蛋白的表达,减低细胞的侵袭力．     

KEAP1基因及其突变位点对非小细胞肺癌细胞株作用的实验初步研究

摘要 目的：研究KEAP1基因及KEAP1基因突变位点对肺癌细胞株的作用。方法：通过Western blot 方法,比较携带KEAP1 基因突变的肺癌细胞株（A549,NCI-H460,NCI-H838）与KEAP1 基因野生型的肺癌细胞株（NCI-H292, NCI-H1299, 95D, SPC-A1）之间,NRF2基因与NRF2下游基因HO-1的蛋白表达水平,检测并比较两组细胞的活性氧（ROS）含量;以新发现的非小细胞肺癌（NSCLC）病人的 KEAP1 体细胞突变作为模板构建 KEAP1 突变质粒,对自身存在 KEAP1 突变的肺癌细胞株A549,通过改造的 pMSCV 逆病毒转染体系,分别构建过表达空载,野生型及突变型 KEAP1 的 A549 稳定细胞株,比较过表达不同质粒的细胞间丙二醛（MDA）含量及 NRF2 下游抗氧化等相关基因的表达水平;通过克隆形成实验检测细胞增殖情况。结果：KEAP1基因突变组肺癌细胞株与KEAP1基因无突变的对照组细胞株相比,NRF2和HO-1蛋白表达显著增高,活性氧水平显著降低（P<0.01）;过表达野生型KEAP1 与过表达空载的 A549细胞相比,NRF2 及其下游基因转录水平表达显著下降（P<0.01）,蛋白水平表达下降,细胞内丙二醛水平显著增高（P<0.01）,克隆形成率显著降低（P<0.01）,而过表达突变型 KEAP1 与过表达空载的 A549细胞相比,NRF2 及其下游基因表达、细胞内丙二醛水平、克隆形成率均无显著差异（P>0.05）。结论：KEAP1基因具有抑癌作用,其突变为失活型突变,突变后KEAP1/NRF2通路激活,KEAP1基因突变可能通过改变细胞的氧化应激水平,促进肺癌的发生发展。     

PTEN基因诱导人胚肾293细胞凋亡和细胞周期停滞

为了研究抑癌基因PTEN过表达对HEK293细胞凋亡和细胞周期停滞的作用,以野生型PTEN和PTEN突变子(T910G)表达质粒分别转染无PTEN表达的人胚肾293细胞,采用细胞质梯度DNA方法检测细胞凋亡,以流式细胞仪分析细胞周期.发现PTEN过表达能够诱导人胚肾293细胞质中出现梯度DNA,293细胞发生凋亡,PTEN过表达改变细胞周期分布,G0/G1期细胞增加13%,S期细胞下降15%.PTEN突变子对细胞凋亡和G1细胞停滞的影响略弱于野生型PTEN.PTEN基因过表达明显下调血小板衍生生长因子(PDGF)诱导的蛋白激酶B(PKB)和p42,p44-促分裂原活化蛋白激酶(MAPK)磷酸化水平,PTEN突变子对p42,p44-MAPK磷酸化水平的调节作用略弱于野生型PTEN.PTEN通过抑制细胞增殖,诱导细胞凋亡而影响细胞生长.     

Survivin基因RNA干扰对肺癌细胞凋亡及增殖的影响

目的:探讨Survivin表达对肺鳞癌细胞的凋亡和增殖的影响.方法:利用siRNA阻抑人肺鳞癌细胞内survivin基因的表达,用RT-PCR和Western Blotting法分析survivin基因mRNA和蛋白的表达,流式细胞术检测细胞凋亡率,细胞集落形成实验检测细胞增殖.结果:(1)Survivin在肺癌细胞中表达.转染Survivin siRNA可在RNA和蛋白水平阻断其表达;(2)转染Survivin siRNA的肺癌细胞凋亡率显著增加;(3)转染Survivin siRNA的肺癌细胞的集落形成率显著降低.结论:阻断Survivin表达可通过增加细胞凋亡率和降低细胞增殖增加肺鳞癌细胞的放疗敏感性.     

IGF-1抑制妊娠合并糖尿病诱导的鼠胚胎细胞凋亡

为研究妊娠合并糖尿病对孕妇及胎儿产生危害的机制,构建妊娠合并糖尿病的昆明小鼠动物模型,检测不同浓度葡萄糖对体外培养胚泡细胞生长的影响．观察不同浓度胰岛素样生长因子-1(insulin-like growth factor-1, IGF-1)对体外高糖环境胚泡细胞发育的影响,利用细胞核DNA双染实验观察不同浓度IGF-1作用下胚泡细胞的凋亡．采用实时定量PCR(RT-PCR)分析不同凋亡相关基因在体外培养胚泡中的表达情况．结果显示,随着葡萄糖浓度的增加,胚泡细胞总数减少,高浓度葡萄糖(≥30 mmol/L)则能显著性抑制胚泡细胞的生长(P < 0.01)．RT-PCR检测发现妊娠合并糖尿病小鼠的胚泡igf-1表达下调,且与葡萄糖的浓度成正相关．凋亡相关基因bcl-2和bcl-xl的表达随着体外IGF-1培养浓度的增加而表达上调,而p53基因和凋亡相关基因Bax的表达则下调．细胞凋亡实验显示,随着IGF-1浓度的增加,体外培养胚泡细胞的凋亡逐渐降低,当IGF-1浓度达到100 μg/L时,几乎未发现细胞凋亡．因此,高血糖能抑制胚泡细胞的生长发育,导致igf-1的表达下调,而IGF-1能抑制胚泡细胞的凋亡,有利于胚泡细胞的生长发育．     

小鼠白细胞介素33真核表达质粒的构建及表达

克隆小鼠IL-33基因构建其真核表达质粒,并转染COS-7细胞检测其表达。提取C57BL/6小鼠肺组织总RNA,经反转录聚合酶链式反应（RT-PCR）扩增小鼠IL-33基因,酶切后插入pcDNA^TM3.1/myc HisA构建其真核表达质粒pcDNA-3.1-IL-33,重组质粒转染COS-7细胞,RT-PCR和免疫印迹法（western blotting）检测目的基因表达。结果显示,pcDNA3.1-IL-33中插入的片段序列测定结果与小鼠IL-33cDNA序列一致,重组质粒转染COS-7细胞后检测到相应mRNA及蛋白表达。成功克隆了小鼠IL-33基因cDNA,并构建其真核表达质粒。     

pcsk9 siRNA对oxLDL诱导的THP-1源性巨噬细胞凋亡的影响

为研究pcsk9基因沉默后对氧化型低密度脂蛋白(oxLDL)诱导THP-1源性巨噬细胞凋亡的影响,用不同浓度oxLDL 处理THP-1源性巨噬细胞48 h,Hoechst33258染色检测细胞凋亡,RT-PCR、Western blot分别检测pcsk9 mRNA、NARC-1蛋白的表达．应用Lipofectamine2000转染3对pcsk9 siRNAs进THP-1源性巨噬细胞中,筛选出最有效的siRNA再转染入THP-1源性巨噬细胞,24 h后加入oxLDL处理 48 h,Hoechst33258染色观察细胞评价细胞凋亡,流式细胞术计数检测细胞凋亡率．结果发现,75 mg/L oxLDL处理THP-1源性巨噬细胞48 h后,Hoechst33258染色可见大量凋亡细胞．同时RT-PCR、Western blot检测发现,pcsk9 mRNA和NARC-1蛋白质表达量均随oxLDL浓度的增加而增加,75 mg/L oxLDL组增加最明显．不同浓度siRNA转染THP-1源性巨噬细胞后,RT-PCR筛选出3对siRNAs的终浓度为80 nmol/L均可出现明显的沉默效应．选取此浓度在蛋白质水平检测基因抑制情况,筛选出最有效的一对siRNA．将筛选出来的siRNA转染细胞24 h后,再用oxLDL处理48 h,Hoechst33258染色及流式细胞计数结果显示,转染siRNA组凋亡明显被抑制．结果表明,在本研究的浓度范围内,随着oxLDL浓度增加pcsk9的表达随之增加,同时,THP-1源性巨噬细胞凋亡也明显增加,75 mg/L oxLDL最明显,pcsk9 mRNA和蛋白质的表达也在该浓度最高．提示pcsk9 siRNA能有效抑制pcsk9基因的表达,从而有效抑制由oxLDL诱导的THP-1源性巨噬细胞的凋亡．     

靶向糖基转移酶shRNA表达质粒对LoVo细胞侵袭和增殖能力的抑制作用

通过构建针对Ｎ-乙酰氨基葡萄糖转移酶Ⅴ(GnT-Ⅴ)的小片段发夹状RNA(shRNA)干扰表达质粒,研究了shRNA表达质粒沉默GnT-Ⅴ基因后对LoVo细胞增殖、黏附以及迁移、侵袭能力的影响．设计了靶向GnT-Ⅴ基因的小干扰RNA(siRNA)靶序列,构建shRNA表达载体并转染人结肠癌LoVo细胞,通过G418筛选建立稳定低表达GnT-Ⅴ基因的细胞株．分别采用半定量逆转录聚合酶链反应(RT-PCR)和蛋白质印迹(Western blot)检测shRNA对GnT-Ⅴ基因mRNA及蛋白质表达的影响．并通过CCK-8增殖实验、异质黏附实验、划痕愈合实验、趋化运动实验、细胞侵袭实验评价pGPU6/GFP/Neo GnT-Ⅴ shRNA对人结肠癌LoVo细胞增殖、黏附以及迁移、侵袭能力的影响．实验成功地构建了GnT-Ⅴ shRNA表达质粒,并且该质粒明显下调GnT-Ⅴ的表达,LoVo GnT-Ⅴ/1564和LoVo GnT-Ⅴ/2224的mRNA水平的抑制率分别为82%和71.5%,蛋白质水平的抑制率分别为68%和56%．选择干扰效率较高的LoVo GnT-Ⅴ/1564进行进一步实验．CCK-8增殖实验显示,与阴性对照组相比,LoVo GnT-Ⅴ/1564的增殖受到明显抑制(P < 0.001),尤以72 h为著;下调GnT-Ⅴ表达可增强LoVo细胞的黏附能力( t = -3.357,P < 0.01),而显著抑制LoVo细胞的趋化运动能力( t = 44.051,P < 0.001);划痕实验结果也显示抑制GnT-Ⅴ表达延长LoVo细胞的愈合时间;用Matrigel胶介导的细胞侵袭实验结果显示,LoVo GnT-Ⅴ/1564和LoVo GnT-Ⅴ/NC的穿膜细胞数分别为(5.10 ± 1.25)个和(39.55 ± 2.16)个,GnT-Ⅴ/1564组较阴性对照组明显减少( t = 61.626,P < 0.001)．结果表明,靶向GnT-Ⅴ的shRNA真核表达质粒可以显著降低GnT-Ⅴ的表达,从而抑制LoVo细胞的增殖、迁移和侵袭能力,因此,该GnT-Ⅴ的siRNA序列可能成为治疗结直肠癌的有效靶点．     

miRNA-21对肺癌细胞放疗敏感性调控及肺损伤的影响

[目的]探究miRNA-21对肺癌细胞放疗敏感性的调控及放疗所致肺损伤的影响。[方法]选取人小细胞肺癌细胞系NCI-H446作为肺癌细胞模型、人支气管上皮细胞HBE作为放疗所致肺损伤细胞模型，取对数生长期NCI-H446和HBE细胞，分为空白对照组(不转染细胞)、阴性对照组(转染阴性对照序列细胞)和anti-miRNA-21组(转染anti-miRNA-21序列细胞),检测各组细胞中miRNA-21表达水平细胞活率、细胞周期进程。[结果]NCI-H446中miRNA-21表达量显著高于BEAS-2B,5.0Gy组的NCI-H446和HBE细胞活率均显著低于0.0Gy组，与0.0Gy比较，2.5、5.0Gy组的NCI-H446和HBE细胞的G2/M期细胞百分比显著增高(P<0.05),G1/S期细胞百分比显著降低，5.0Gy γ照射后，在8 h前，NCI-H446细胞中的miRNA-21表达水平显著上调，8 h后逐渐回落；在12 h前，HBE细胞中的miRNA-21表达水平显著上调，12 h后逐渐回落。转染后，anti-miRNA-21组NCI-H446和HBE细胞中的miRNA-...     

肿瘤细胞不同程度表达HLA-G对NK细胞杀伤活性影响的分析

目的:分析肿瘤细胞不同程度表达HLA-G对NK细胞杀伤活性影响。方法:以HepG2、NCI-H446、K562为研究对象,基因克隆建立表达载体,并将HLA-G/pGEM-T质粒转染到HepG2、NCI-H446及K562上。测定HepG2、NCI-H446及K562细胞内及细胞表面HLA-G的表达。结果:转染后的HEPG2-G、NcI-H446-G、K562-G细胞表面HEPG2-G的表达量依次为33.25%、45.68%、38.43%。3组比较,差异具有统计学意义(P<0.05)。     

miR-195通过靶向调控趋化因子5促进胃癌细胞增殖、转移及侵袭的实验研究

目的:研究miR-195通过靶向调控趋化因子5促进胃癌细胞增殖、转移及侵袭的分子机制。方法:选取MGC803及NCI-N87细胞,根据转染不同分为:miR-NC组(空质粒),miR-195-mimics组(模拟序列)。实时荧光定量PCR法检测miR-195表达;MTT检测细胞增殖能力;Transwell侵袭实验检测细胞侵袭力;细胞划痕实验检测细胞转移能力;流式细胞术检测细胞凋亡情况;Western blot检测chemokine 5表达水平;Spearman相关分析miR-195及chemokine 5相关性。荧光素酶实验验证miR-195与chemokine 5的靶向关系。结果:miR-195-mimics组细胞miR-195水平高于miR-NC组(P0.05);miR-195 mimics组第1、2、3、4 d细胞活力低于miR-NC组(P0.05);miR-195 mimics组G1细胞高于miR-NC组,G2期、S期细胞低于miR-NC组,G2/S期细胞比值低于miR-NC组(P0.05);miR-195 mimics组划痕距离大于miR-NC组(P0.05);miR-195 mimics组细胞侵袭数低于miR-NC组(P0.05);miR-195-mimics组细chemokine 5蛋白含量低于miR-NC组(P0.05);miR-195 m RNA水平与chemokine 5蛋白含量负相关(r=-0.398,P=0.00);miR-195可直接靶向chemokine 5。结论:miR-195可通过靶向chemokine 5促进胃癌MGC803及NCI-N87细胞的增殖、转移及侵袭。     

An anthraquinone derivative from Luffa acutangula induces apoptosis in human lung cancer cell line NCI-H460 through p53-dependent pathway

The current study was designed to evaluate the in vitro antiproliferative activity of 1,8-dihydroxy-4-methylanthracene-9,10-dione (DHMA) isolated from the Luffa acutangula against human non-small cell lung cancer cell line (NCI-H460). Induction of apoptosis and reactive oxygen species (ROS) generation was determined through fluorescence microscopic technique. Quantitative real-time PCR and western blotting analysis was carried out to detect the expression of pro-apoptotic (p53, p21, caspase-3, Bax, GADD45A, and ATM) and anti-apoptotic (NF-κB) proteins in NCI-H460 cell line. In silico studies also performed to predict the binding mechanism of DHMA with MDM2-p53 protein. The DHMA inhibited the cell viability of NCI-H460 cells in a dose-dependent manner with an IC₅₀ of about 50?µg/ml. It significantly reduced cell viability correlated with induction of apoptosis, which was associated with ROS generation. The apoptotic cell death was further confirmed through dual staining and DNA fragmentation assay. DHMA significantly increased the expression of anti-apoptotic protein such as p53, p21, Bax, and caspase-3 but downregulated the expression of NF-κB in NCI-H460 cell line. In silico studies demonstrate that DHMA formed hydrogen bond interaction with key residues Trp26, Phe55 and Lys24 by which it disrupt the binding of p53 with MDM2 receptor. These findings suggested that DHMA induces apoptosis in NCI-H460 via a p53-dependent pathway. This the first study on cytotoxic and apoptosis inducing activity of DHMA from L. acutangula against NCI-H460 cell line. Therefore, DHMA has therapeutic potential for lung cancer treatment.     

Evodiamine Induces G2/M Arrest and Apoptosis via Mitochondrial and Endoplasmic Reticulum Pathways in H446 and H1688 Human Small-Cell Lung Cancer Cells

The goal of this study was to evaluate the ability of EVO to decrease cell viability and promote cell cycle arrest and apoptosis in small cell lung cancer (SCLC) cells. Lung cancer has the highest incidence and mortality rates among all cancers. Chemotherapy is the primary treatment for SCLC; however, the drugs that are currently used for SCLC are less effective than those used for non-small cell lung cancer (NSCLC). Therefore, it is necessary to develop new drugs to treat SCLC. In this study, the effects of evodiamine (EVO) on cell growth, cell cycle arrest and apoptosis were investigated in the human SCLC cell lines NCI-H446 and NCI-H1688. The results represent the first report that EVO can significantly inhibit the viability of both H446 and H1688 cells in dose- and time-dependent manners. EVO induced cell cycle arrest at G2/M phase, induced apoptosis by up-regulating the expression of caspase-12 and cytochrome C protein, and induced the expression of Bax mRNA and by down-regulating of the expression of Bcl-2 mRNA in both H446 and H1688 cells. However, there was no effect on the protein expression of caspase-8. Taken together, the inhibitory effects of EVO on the growth of H446 and H1688 cells might be attributable to G2/M arrest and subsequent apoptosis, through mitochondria-dependent and endoplasmic reticulum stress-induced pathways (intrinsic caspase-dependent pathways) but not through the death receptor-induced pathway (extrinsic caspase-dependent pathway). Our findings suggest that EVO is a promising novel and potent antitumor drug candidate for SCLC. Furthermore, the cell cycle, the mitochondria and the ER stress pathways are rational targets for the future development of an EVO delivery system to treat SCLC.     

miR-22 enhances the radiosensitivity of small-cell lung cancer by targeting the WRNIP1

Small-cell lung cancer (SCLC) is an aggressive malignancy characterized by high cellular proliferation and early distant metastasis. Our study aimed to explore the effect of miR-22-3p (miR-22, for short) on SCLC radiosensitivity and its molecular mechanisms. The expression level of miR-22 was evaluated in a human normal lung epithelial cell line and a human SCLC cell line, and cell apoptosis and migration were detected. The expression of the miR-22 direct target WRNIP1 mRNA and protein were explored. Five differentially expressed genes were detected. The miR-22 expression in NCI-H446 was significantly decreased, and miR-22 overexpression significantly promoted cell apoptosis. miR-22 overexpression could significantly inhibit the cell migration of SCLC cells, and miR-22 had a negative regulatory effect on WRNIP1 mRNA and protein levels. KLK8 was downregulated, and the messenger RNA (mRNA) of four other genes (PC, SCUBE1, STC1, and GPM6A) was upregulated mRNA in cells overexpressing miR-22, which was in accordance with the bioinformatics analysis. miR-22 could enhance the radiosensitivity of SCLC by targeting WRNIP1.     

Lentiviral vector-mediate ATG3 overexpression inhibits growth and promotes apoptosis of human SKM-1 cells

Based on the nested case–control study cohort and gene expression profile, we have picked up a subset of six genes to distinguish the leukemia group and control group stably. ATG3 is the only down regulated gene. This research is to investigate the effect of ATG3 gene over expression by lentivirus on SKM-1 cell line and myelodysplastic syndrome to leukemic transformation. Human SKM-1 cells were transfected with ATG3–GFP recombinant lentiviral vectors and compared with cells transfected with GFP lentiviral vectors. Western blot was performed to detect the ATG3 protein. Cell proliferation was assessed by cell counting kit-8. Cell vitality was tested by Trypan Blue. Cell apoptosis was determined by Annexin V Apoptosis Detection Kit APC. Observe and compare the changes on growth curve, cell vitality and cell apoptosis. After 72 h of transfection, satisfactory transfection efficiency (> 90 %) was observed. SKM-1 cell line showed a statistically significant (P < 0.05) overexpression of ATG3, parallel to significantly (P < 0.05) inhibited cell proliferation. The cell vitality of ATG3 overexpression was significantly (P < 0.05) lower than negative control. Cell apoptosis analysis by flow cytometer demonstrated decreased proportion of early apoptosis and increased that of late apoptosis and death (P < 0.05). Over expressed ATG3 gene and protein, the SKM-1 cell line was inhibited in proliferation and cell vitality. It was promoted from early apoptosis to late apoptosis and death. The malignancy of SKM-1 cell line was decreased after transfection. ATG3 gene and its gene family may play an important role in transformation of myelodysplastic syndrome.     

Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1α induction

Survivin is a member of the inhibitor of apoptosis protein family that is overexpressed in various tumors and is important in restricting apoptosis. Understanding the molecular events of apoptosis may provide information for developing novel therapeutic agents targeting non-small cell lung cancer (NSCLCs). This study used three human NSCLC cell lines, NCI-H1299, SK-MES-1, and NCI-H460. Changes in apoptosis, the mRNA and protein expression of survivin under normoxia and hypoxia, with or without rapamycin treatment were analyzed. In addition, siRNA and ChIP assay were further applied to demonstrate the role of hypoxia-inducible factor 1 (HIF-1)α in regulating survivin expression regulation under hypoxia during rapamycin induced NSCLC cell apoptosis. Treatment with rapamycin resulted in significantly increased NSCLC cells apoptosis under hypoxia. We demonstrated for the first time that rapamycin inhibited hypoxia-induced survivin expression in NSCLC cell lines. We further demonstrated that HIF-1α participated in hypoxia-induced survivin expression, and that rapamycin inhibited hypoxia-induced HIF-1α expression by enhancing its degradation. The results above collectively showed that rapamycin inhibits HIF-1α-induced survivin expression under hypoxia to induce NSCLC apoptosis.     

DADS对人小细胞肺癌NCI-H446细胞系增殖抑制的研究

目的：研究二烯丙基二硫（diallyldisulfide,DADS）对人小细胞肺癌NCI．H446细胞增殖的抑制作用,并探讨其作用机制。方法：体外培养NCI-H446细胞,采用MTT、细胞计数实验方法检测DADS抑制NCI—H446细胞增殖;通过HE染色和AO—EB荧光染色方法,观察DADS处理后NCI—H446细胞的形态学改变。结果：MTT结果显示：DADS作用于NCI—H446细胞48h后,代谢MTT的能力明显降低,显示出较强的细胞毒性反应,IC50值介于20-40μg／ml之间。细胞计数结果表明：DADS作用于NCI—H446细胞后,随DADS浓度增加NCI—H446细胞倍增时间延长。HE染色显示：NCI—H446细胞经DADS处理24h后,与对照组相比,细胞体积变小,胞浆丰富,细胞核变小,染色变淡。AO-EB荧光染色显示：NCI-H446细胞经DADS处理24h后,与对照组相比,细胞皱缩、呈圆形,胞质黄色或橘红色,细胞核或细胞质内可见致密浓染的黄绿色或橘红色荧光,并可见橘红色碎片且随DADS浓度增加,随DADS浓度增加细胞密度逐渐减少。结论：DADS能抑制体外培养的NCI—H446细胞增殖,作用效果与药物浓度及作用时间相关。